Instructions for providing comments[edit source]
Click “Reply” in the bottom right corner and an empty comment box will open. The exact wording of your comment will appear in the discussion thread, but cannot be edited by other reviewers.
2) Copy and paste the sentence/paragraph to which your feedback relates, leave a blank line and then include your comment or suggested change.
3) Statements regarding the inclusion/exclusion of issues should be clearly supported by scientific evidence, and specifically outline the relevance of the suggested material to the guidelines.
Full citation of the reference/s should be provided for consideration.
4) If you have identified any gaps or errors in the content please suggest suitable text for inclusion.
5) Please highlight any terms that need to be defined in the Glossary.
DON’T FORGET TO SAVE YOUR COMMENT!
COSA on behalf of Gabrielle Cehic and Steven Unger (Flinders Medical Centre, SA)
- A prerequisite is the need to demonstrate that known tumour sites have sufficient uptake of diagnostic 111In-Octreotide or 68Ga-labelled somatostatin analogues, to indicate that therapeutic levels of internal radiation could be potentially delivered by administration of 177Lu-octreotate radiopeptide therapy.
Comment: Recommend also adding Lutetium-177 Octreotide SPECT for scanning.
- Patients with clinically symptomatic residual disease following surgical debulking can reasonably be offered radiopeptide therapy. However, in the absence of symptoms or progressive disease, such treatment should only be offered in the setting of a clinical trial.
Comment: The final line recommends therapy only as part of a clinical trial. Given the lack of suitable alternatives and proven safety, consider rewording to cover use outside of a clinical trial (i.e. similar to compassionate use described under “Access to radiopeptide therapy in Australasia”).